市場調査レポート
商品コード
1370366
バイオチップ市場:世界の産業動向、シェア、規模、成長、機会、2023-2028年予測Biochips Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
バイオチップ市場:世界の産業動向、シェア、規模、成長、機会、2023-2028年予測 |
出版日: 2023年10月15日
発行: IMARC
ページ情報: 英文 144 Pages
納期: 2~3営業日
|
世界のバイオチップ市場規模は2022年に169億米ドルに達しました。今後、IMARC Groupは、2023年から2028年にかけて15.8%の成長率(CAGR)を示し、2028年までに406億米ドルに達すると予測しています。慢性疾患の蔓延、個別化医療への嗜好の高まり、がん細胞の早期発見ニーズの高まりが、市場を牽引する主な要因の一つです。
バイオチップは、複数の生化学反応を同時に短時間で実行するように設計された小型化医療機器を指します。バイオチップは、固体基板表面上に配置された微小検査部位またはマイクロアレイの集合体からなります。デオキシリボ核酸(DNA)、タンパク質、酵素、ラボオンチップとして広く利用されています。コンパクトで、強力で、高速で、使いやすく、重要な知見を正確に得ることができます。個人の医療情報や財務情報の保存に非常に適しており、人間や動物を簡単に追跡することができます。チップは体内に埋め込まれ、患者の健康状態や体内の生物学的プロセスをモニター、分析、制御するのに役立ちます。これに加えて、潜在的な危険の特定、安全な環境の確保、意思決定の改善にも役立ちます。その結果、バイオチップは、遺伝子、腫瘍、炎症診断、分子分析など、世界中の個人の間で応用されています。
現在、糖尿病、血圧、慢性閉塞性肺疾患(COPD)などの慢性疾患の有病率が上昇しており、これが世界市場の成長を支える重要な要因の一つとなっています。これに加えて、ゲノミクス、プロテオミクス、分子診断におけるバイオチップの利用が大衆の間で拡大していることも、市場にプラスの影響を与えています。さらに、バイオチップが提供する様々な特典、例えば、時間と費用の削減、重い装置を必要とせずに高いスループットを提供する能力などが市場の成長に寄与しています。これとは別に、世界中のヘルスケア業界では、時間節約と高品質のデバイスに対する需要が高まっています。これに加えて、個人の間で数多くの病気を治療するための個別化医療や次世代シーケンシング(NGS)に対する嗜好が高まっていることも、市場の成長を後押ししています。これに加えて、体内のがん細胞の早期発見を目的としたバイオチップの採用が増加しており、業界の投資家に有利な成長機会を提供しています。さらに、高齢者人口の増加と、世界の医薬品開発・発見のためのバイオチップに対する需要の高まりは、有利な市場展望を提供しています。さらに、マイクロ流体ベースのデバイスにおける生物医学的進歩や、感染症の初期診断で迅速な結果を提供するラボオンチップの技術革新が、市場の成長を後押ししています。
The global biochips market size reached US$ 16.9 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 40.6 Billion by 2028, exhibiting a growth rate (CAGR) of 15.8% during 2023-2028. The growing prevalence of chronic diseases, increasing preferences for personalized medicines, and rising need for early detection of cancerous cells represent some of the key factors driving the market.
Biochips refer to a miniaturized medical device that is designed to perform several biochemical reactions simultaneously in less time. They comprise a collection of micro-test sites or microarrays, which are arranged on the surface of a solid substrate. They are widely available as deoxyribonucleic acid (DNA), protein, enzyme, and lab-on-a-chip. They are compact, powerful, fast, easy to use, and provide critical insights accurately. They are highly suitable for storing personal medical and financial information and can easily trace human beings or animals. They are implanted in the body and assist in monitoring, analyzing, and controlling the health of a patient and biological processes in the body. Besides this, they aid in identifying potential hazards, ensuring a safe environment, and improving decision-making. As a result, biochips find applications for gene, oncology, and inflammatory diagnosis and molecular analysis among individuals across the globe.
At present, rising prevalence of chronic diseases, such as diabetes, blood pressure, and chronic obstructive pulmonary disease (COPD), represents one of the key factors supporting the growth of the market around the world. Besides this, the growing utilization of biochips in genomics, proteomics, and molecular diagnostics among the masses is positively influencing the market. Additionally, various benefits offered by biochips, such as reduction of time and money and the ability to provide high throughput without any requirement of heavy instruments, is contributing to the growth of the market. Apart from this, there is a rise in demand for time-saving and high-quality devices in the healthcare industry across the globe. This, coupled with the increasing preference for personalized medicines and next-generation sequencing (NGS) to treat numerous diseases among individuals, is propelling the growth of the market. In addition to this, the rising adoption of biochips for early detection of cancerous cells in the body is offering lucrative growth opportunities to industry investors. Moreover, the increasing geriatric population, along with the growing demand for biochips for drug development and discovery around the world, is offering a favorable market outlook. Furthermore, the biomedical advancement in microfluidic-based devices and innovation in lab-on-a-chip to offer quick results at initial diagnosis of infectious disease is impelling the growth of the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global biochips market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product type, fabrication technique, analysis method, application and end user.
DNA Chip
Protein Chip
Lab-On-a-Chip
Enzyme Chip
The report has provided a detailed breakup and analysis of the biochips market based on the product type. This includes DNA chip, protein chip, lab-on-a-chip, and enzyme chip. According to the report, DNA chip represented the largest segment.
Microarray
Microfluidic
A detailed breakup and analysis of the biochips market based on the fabrication technique has also been provided in the report. This includes microarray and microfluidic. According to the report, microarray accounted for the largest market share.
Electrophoresis
Luminescence
Mass Spectrometry
Electrical Signals
Magnetism
A detailed breakup and analysis of the biochips market based on the analysis method has also been provided in the report. This includes electrophoresis, luminescence, mass spectrometry, electrical signals, and magnetism. According to the report, electrophoresis accounted for the largest market share.
Molecular Analysis
Hybridization
Protein
Immunological
Biomolecules
Biomarker
Others
Diagnosis
Gene Diagnosis
Oncology
Inflammatory
Others
Non-Biological Usage
A detailed breakup and analysis of the biochips market based on the application has also been provided in the report. This includes molecular analysis (hybridization, protein, immunological, biomolecules, biomarker, and others), diagnosis (gene diagnosis, oncology, inflammatory, and others), and non-biological usage. According to the report, diagnosis (gene diagnosis, oncology, inflammatory, and others) accounted for the largest market share.
Pharmaceutical and Biotechnology Companies
Hospitals and Diagnostics Centers
Academic and Research Institutes
Others
A detailed breakup and analysis of the biochips market based on the end user has also been provided in the report. This includes pharmaceutical and biotechnology companies, hospitals and diagnostics centers, academic and research institutes, and others. According to the report, pharmaceutical and biotechnology companies accounted for the largest market share.
North America
United States
Canada
Europe
Germany
France
United Kingdom
Spain
Russia
Italy
Others
Asia Pacific
China
Japan
India
South Korea
Australia
Others
Latin America
Mexico
Brazil
Argentina
Others
Middle East and Africa
Turkey
Saudi Arabia
United Arab Emirates
Others
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Spain, Russia, Italy, and others); Asia Pacific (China, India, Japan, South Korea, Australia, and others); Latin America (Mexico, Brazil, Argentina, and others); and the Middle East and Africa (Turkey, Saudi Arabia, United Arab Emirates, and others). According to the report, North America (the United States and Canada) was the largest market for biochips. Some of the factors driving the North America biochips market included the growing prevalence of lifestyle diseases, rising geriatric population, presence of several biotechnology companies, etc.
The report has also provided a comprehensive analysis of the competitive landscape in the global biochips market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Agilent Technologies, Inc., bioMerieux SA, Bio-RAD Laboratories, Inc., CapitalBio Corporation, Dynamic Biosensors GmbH, EMD Millipore Corporation, Fluidigm Corporation, Illumina, Inc., Perkinelmer, Inc., Thermo Fisher Scientific, Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.